Skip to content

National Survey on Infiltrative Breast Cancer

National Prospective Survey on Women With a Diagnosis of Infiltrative Breast Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00696527
Acronym
CSI
Enrollment
1500
Registered
2008-06-12
Start date
2007-06-30
Completion date
2008-07-31
Last updated
2010-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infiltrative Breast Cancer

Keywords

Infiltrative breast cancer-Clinical practice, Women with infiltrative breast cancer

Brief summary

The purpose of this observational study is to describe radiological, clinical and histological characteristics of women with infiltrative breast cancer.

Interventions

None listed

Sponsors

AstraZeneca
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women\> or = 18 years old * Women with newly diagnosis of infiltrative breast cancer * Agree to take part in this study

Exclusion criteria

* Women with other malignant tumor (except in situ cervical carcinoma or treated basal cell carcinoma) * Women with in situ ductal carcinoma or in situ lobular carcinoma

Design outcomes

Primary

MeasureTime frame
Radiological, Clinical and Histological characteristicsOnce

Secondary

MeasureTime frame
Treatments: Surgery, radiotherapy, chemotherapy, hormonotherapy.Once

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026